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Abstract In Drosophila, the Toll family of proteins mediates
the innate immune response. Toll is activated by Spaetzle, which
is generated in response to pathogens via a serine protease
cascade. We wished to investigate if lipopolysaccharides (LPS)
might activate Toll-like receptor (TLR) 4 via a serine protease in
humans. The serpin antithrombin III (ATIII) and the thrombin
inhibitor hirudin both inhibited nuclear factor (NF)-UB activation
by LPS and Lipid A. ATIII and hirudin were also able to inhibit
LPS-induced NF-UB activation in cells stably transfected with
TLR4. These results suggest that LPS may activate a
mammalian serine protease, which generates a product required
for TLR4 signalling. ß 2001 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Vertebrates have developed a sophisticated immune system
to defend themselves against microbial infections, involving
both innate and adaptive immune components. In Drosophila
the Toll family of proteins mediates the innate immune re-
sponse [1,2]. Toll-like receptors (TLR) also occur in humans,
where 10 have been found [3]. Similar to Drosophila Toll, all
of these possess a Toll/interleukin-1 (IL-1) receptor (TIR) cy-
toplasmic domain responsible for signal transduction [4,5].
Toll and TLRs activate Rel family transcription factors,
which regulate host defense gene expression [6,7].
The role of Toll is to respond to fungal pathogens, while
TLRs respond to di¡erent pathogen-derived products. Most
notably, TLR4 responds to lipopolysaccharide (LPS) from
Gram-negative bacteria [8,9], TLR2 responds to peptidogly-
can from Gram-positive bacteria [10,11], TLR9 responds to
bacterial CpG DNA [12], and TLR5 responds to bacterial
£agellin [13]. TLRs have therefore been identi¢ed as so-called
pathogen recognition receptors, which sense pathogen-associ-
ated molecular patterns (PAMPs). In spite of the similarities
between the Toll system in Drosophila and mammals, there is
evidence for a di¡erence between them. In Drosophila, an
extracellular serine protease cascade generates a proteolyti-
cally cleaved peptide, Spaetzle, the ligand for Toll, in response
to fungi [14,15]. This cascade is inhibited by the serpin
Spn43Ac [16]. In mammals, LPS has been proposed to act
as the putative ligand for TLR4. The most convincing evi-
dence for LPS binding to TLR4 has come from a cross-link-
ing study in a cell line over-expressing TLR4 and two addi-
tional components needed for LPS signalling, MD2 and
CD14. LPS was found to be cross-linked to all three [17].
Due to the fact that Toll action can be blocked by the
serpin Spn43Ac in Drosophila, we wished to investigate
whether the LPS response in mammals might also be sensitive
to a serpin. We have found that acute treatment of the human
monocyte cell line THP-1, or HEK 293 cells stably transfected
with TLR4, with the serpin antithrombin III (ATIII), or the
thrombin inhibitor hirudin, block nuclear factor (NF)-UB ac-
tivation by LPS and Lipid A. These results provide the ¢rst
indication that LPS may activate an extracellular serine pro-
tease in mammals, which is required for LPS-induced NF-UB
activation.
2. Materials and methods
2.1. Cell culture
The human monocyte cell line THP-1 was purchased from Euro-
pean Collection of Cell Cultures (ECACC), and maintained in RPMI
1640 (Sigma, USA), supplemented with 10% foetal calf serum (FCS,
Sigma, USA) and 2 mM L-glutamine (Gibco, UK), 5% CO2. The
stably transfected cell line HEK 293-TLR4 was a kind gift from
Prof. Douglas Golenbock (Boston Medical Centre, Boston, MA,
USA), and were maintained in RPMI 1640, 10% FCS, 2 mM L-glu-
tamine, 5% CO2 supplemented with selection antibiotic 25 Wg/ml pu-
romycin.
2.2. Materials
Chromozym TH was supplied by Boehringer Mannheim (Mann-
heim, Germany). The K-isoform of both ATIII and the latent ATIII
were a kind gift of Prof. Robin Carrell (Cambridge University, UK).
Recombinant leech hirudin [Lys47]rHV2 variant, LPS serotype 026:B6
and Lipid A were supplied by Sigma. The 22-bp oligonucleotide,
containing the NF-UB consensus sequence and T4 polynucleotide
kinase kit were from Promega Corp (WI, USA). [Q-32P]ATP (3000
Ci/mol) is from Amersham
2.3. Nuclear extract preparation and electrophoretic mobility shift
assays (EMSA)
Assays were conducted as previously described [18]. Brie£y, THP-1
cells were resuspended in serum-free RPMI 1640 at 1U106/ml. Cells
were pre-treated with relevant concentrations of proteins for 1 min,
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stimulated with LPS as before, and incubated for a further 60 min at
37‡C. Experiments using stably transfected HEK 293-TLR4 cells were
performed as above, however, cells were seeded at 5U104/ml, 48 h
prior to stimulation. Media were replaced with serum-free RPMI
prior to simulation. Nuclear extracts were prepared by replacement
of media from cells with ice-cold hypotonic bu¡er. The subsequent
cell pellet was lysed and placed on ice for 10 min. Nuclear-associated
proteins were extracted and maintained on ice for 20 min. Following
centrifugation, the supernatant was mixed with storage bu¡er and
used immediately, or frozen at 320‡C. Protein concentrations were
determined using the method of Bradford [19] and extracts stored at
320‡C. In the EMSA, nuclear extracts were incubated for 30 min
with 10 000 cpm of a 22-bp DNA fragment oligonucleotide containing
the NF-UB consensus sequence previously been labelled with
[Q-32P]ATP, in the presence of poly(dI.dC) and 10U binding bu¡er.
Incubated mixtures were subjected to electrophoresis on native 5%
(w/v) polyacrylamide gels, which were subsequently dried and auto-
radiographed. Poly(dI.dC) was supplied by Pharmacia (Uppsala, Swe-
den).
2.4. Protease assay
THP-1 cells (7.5U104/ml) were resuspended in freshly prepared
RPMI 1640 (phenol-red-free) containing 2% FCS in 96 well plates.
Cells were stimulated with 10 Wg/ml of LPS for 3 min. 30-Wl samples
were removed and diluted into 170 Wl of Chromozym TH (1.25 mg/
ml) dissolved in phenol-red-free RPMI 1640, 2 mM L-glutamine.
Chromozym TH is a tosyl-glycyl-prolyl-arginine-4 nitranilide acetate
substrate, with speci¢city for ‘thrombin-like’ proteases. Absorbance
readings were taken at the indicated time points. Results are displayed
as arbitrary absorbance units, displayed as increase in absorbance
units in regard to time zero, per time point.
2.4.1. Statistical analysis. Signi¢cance was evaluated using the
Student’s t-test for unpaired data.
3. Results
3.1. ATIII and hirudin inhibit LPS-mediated NF-UB activation
We ¢rst investigated whether the serpin, ATIII, a plasma
inhibitor of thrombin-like proteases, could inhibit LPS-medi-
ated NF-UB activation [20]. As shown in Fig. 1, ATIII was
e¡ective in reducing LPS-mediated NF-UB activation if cells
were pre-treated for no more than 1^5 min. Simultaneous
addition of ATIII and LPS had no e¡ect, while longer pre-
treatments were found to be ine¡ective in reducing NF-UB
activation. The inhibitor pre-treatment time is therefore crit-
ical for an inhibitory e¡ect to be observed. This is presumably
due to endogenous serine protease activity of the cells, which
would inactivate the ATIII in longer pre-treatment times. The
failure of co-incubation by ATIII to inhibit suggests that the
activation of the protease by LPS is more rapid than the
inhibitory e¡ect of ATIII.
Using a pre-treatment time of 1 min, we next pre-treated
cells with a range of concentrations of ATIII. As can be seen
in Fig. 2A, while ATIII was able to inhibit LPS-mediated NF-
UB activation over a broad concentration range of 0.5^20 Wg/
ml, optimal inhibition was achieved with 10 Wg/ml.
In plasma, ATIII binds heparin, thereby increasing its in-
hibitory e¡ect against thrombin [21]. We found however, that
heparin had no e¡ect on either inhibitory or sub-inhibitory
levels of ATIII and its ability to inhibit LPS-mediated activa-
tion of NF-UB (data not shown).
To further examine the e¡ect of ATIII, we also tested
ATIII against Lipid A, the synthetic active moiety of LPS
[22]. Lipid A does not contain lipoproteins or other contam-
inants that have previously been shown to induce NF-UB
activation [23]. Fig. 2B clearly illustrates the ability of ATIII
to abrogate Lipid A-induced NF-UB activation over the same
concentration range as that observed for LPS.
We next wished to determine if hirudin, another thrombin
inhibitor [24], could inhibit LPS-mediated NF-UB activation.
As shown in Fig. 2, hirudin inhibited NF-UB activation by
Fig. 1. Pre-treatment time with ATIII is crucial in mediating inhibi-
tory e¡ect on NF-UB activation by LPS. THP-1 cells (1U106/ml)
were resuspended in serum-free media, and pre-treated with 10 Wg/
ml ATIII for indicated times. Cells were stimulated with LPS (100
ng/ml) and incubated for a further 60 min. Nuclear extracts were
prepared and assayed for NF-UB activation by EMSA. Identical re-
sults were obtained in two further experiments.
Fig. 2. ATIII and hirudin inhibit both LPS- and Lipid A-mediated
NF-UB activation. THP-1 cells (1U106/ml) were resuspended in se-
rum-free media, and pre-treated with 0.5^20 Wg/ml ATIII (A, B) or
0.5^20 units/ml hirudin (C, D) for 1 min. Cells were stimulated with
either 100 ng/ml LPS (A, C) or 2 Wg/ml Lipid A (B, D) and incu-
bated for a further 60 min. Nuclear extracts prepared and assayed
for NF-UB activation by EMSA. Identical results were obtained in
a further experiment.
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both LPS (Fig. 2C) and Lipid A (Fig. 2D), over a concen-
tration range of 1^20 units/ml.
Thrombin has previously been shown to activate NF-UB
[25]. We wished to determine if thrombin was responsible
for the e¡ect observed here. Treatment of THP-1 cells with
thrombin (10^1000 Wg/ml), failed to induce activation of NF-
UB (data not shown). It has also previously been shown that
thrombin is able to potentiate LPS activation of cells [26]. We
found however, that thrombin failed to potentiate NF-UB
activation at sub-inducible LPS concentrations combined
with a range of thrombin concentrations (10^1000 Wg/ml)
(data not shown).
Taken together, these results would suggest that LPS acti-
vation of NF-UB requires the activation of a protease that is
inhibited by ATIII and hirudin, but importantly, does not
involve free thrombin.
3.2. ATIII inhibition is speci¢c for LPS-induced
NF-UB activation
We next con¢rmed that the e¡ect of ATIII requires its
serpin activity. Cells were pre-treated with both ATIII and
an inactive latent form of ATIII (L-ATIII), the inhibitory
loop of which is inserted into the A-L sheet and is thus in-
accessible to proteases [27]. Fig. 3 demonstrates that L-ATIII
(10 Wg/ml) was unable to inhibit LPS-mediated NF-UB acti-
vation. Higher concentrations of L-ATIII also had no e¡ect
(data not shown).
We also tested the speci¢city of ATIII with respect to LPS,
by testing the e¡ect of two other NF-UB activators, IL-1 and
tumour necrosis factor (TNF)-K.
These two cytokines have previously been shown to activate
NF-UB [28], and in the case of IL-1, require a similar signal
transduction pathway as LPS to induce NF-UB nuclear trans-
location [4^7]. As shown in Fig. 3B, ATIII was unable to
inhibit NF-UB activation induced by either IL-1 or TNFK.
This result would suggest that the inhibitory e¡ect of ATIII
is not a¡ecting common signal transduction events to NF-UB
within the cytosol.
3.3. ATIII and hirudin inhibit LPS-mediated NF-UB activation
via TLR4
We also tested the e¡ect of ATIII on NF-UB activation by
LPS in HEK 293 cells stably transfected with TLR4. Parental
293 cells do not respond to LPS (not shown). As can be seen
in Fig. 4, ATIII was able to inhibit LPS-mediated NF-UB
activation. Hirudin at 10 units/ml was also able to reduce
this e¡ect. However, NF-UB activation by LPS was una¡ected
by L-ATIII (10 Wg/ml).
3.4. LPS induces activation of a thrombin-like protease
We next wished to investigate whether LPS could induce
the rapid activation of a serine protease in mammalian cells.
THP-1 cells were therefore treated with LPS and protease
activity monitored using a substrate that is speci¢cally cleaved
by thrombin-like proteases. As demonstrated in Fig. 5, while
THP-1 cells demonstrate considerable basal protease activity
in non-stimulated cells, there is an increase in protease activity
observed within 7.5 min post-stimulation. This protease activ-
ity was signi¢cantly enhanced above non-stimulated basal ac-
tivity between 15 and 30 min post-LPS treatment. By 60 min
no di¡erence between untreated and stimulated cells was ob-
served. These results suggest that LPS can induce a thrombin-
like protease activity over basal activity, in a time-dependent
manner in THP-1 cells.
4. Discussion
In Drosophila, Toll responds to fungal pathogens [1,2]. Ge-
netic evidence suggests that a serine protease cascade gener-
ates Spaetzle, the putative ligand of Toll [14] (although there
are no direct binding studies). Additional data on the possi-
bility of a serine protease cascade has been obtained. Loss of
function mutation of the serpin, Spc43Ac, leads to constitu-
tive Spaetzle and Toll activation [14^16]. Though mammalian
Fig. 3. Speci¢city of ATIII inhibitory e¡ect. A: THP-1 cells
(1U106/ml) were resuspended in serum-free media, and pre-treated
for 1 min with either 10 Wg/ml ATIII or 10 Wg/ml L-ATIII. Cells
were stimulated with 100 ng/ml LPS and incubated for a further 60
min. Nuclear extracts prepared and assayed for NF-UB activation
by EMSA. Similar results were obtained in a further experiment. B:
THP-1 cells (1U106/ml) were resuspended in serum-free media, and
then indicated cells pre-treated with 10 Wg/ml ATIII for 1 min. Cells
were then stimulated with either 5 ng/ml TNFK or 1 ng/ml IL-1
and incubated for a further 60 min. Nuclear extracts prepared and
assayed for NF-UB activation by EMSA. Similar results were ob-
tained in a further experiment.
Fig. 4. ATIII and hirudin inhibit LPS-induced NF-UB activation by
TLR4. Stably transfected HEK 293-TLR4 cells (5U104/ml) were
seeded 48 h prior to treatment. Cells were pre-treated for 1 min
with indicated serine protease inhibitor, then stimulated with 200
Wg/ml LPS and incubated for a further 60 min. Nuclear extracts
were prepared and assayed for NF-UB activation by EMSA. Similar
results were obtained in a further experiment.
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TLR4 has been described as the receptor for LPS [8,9], no
direct binding studies have been performed and the a⁄nity of
the complex for LPS has not been determined. Prompted by
this study in Drosophila on Spc43Ac, we tested the e¡ect of
the serpin ATIII on NF-UB activation by LPS in the human
monocyte cell line THP-1. ATIII has been shown to protect
animals from LPS-induced septic shock and also been shown
to inhibit induction of IL-6 (a NF-UB-dependent gene) by
LPS.
We found that ATIII was able to speci¢cally inhibit NF-UB
activation induced by LPS over a range of concentrations.
Crucially, the e¡ect of ATIII was time-dependent. The pro-
tease activity assay we carried out suggested a high basal
thrombin-like protease activity. ATIII would presumably be
inactivated by the endogenous activity, limiting its e⁄cacy.
Co-incubation of ATIII with LPS did not result in inhibition,
suggesting that the LPS-activated protease proceeds at a faster
rate than ATIII inhibition.
The e¡ect of ATIII required its serpin activity since an
inactive form of ATIII was unable to inhibit LPS-mediated
NF-UB activation. ATIII was able to reduce LPS-induced
activation of NF-UB by TLR4. This result suggests the possi-
bility that a protease generates a product that is able to acti-
vate TLR4. It is possible that the protease being activated is
thrombin, since hirudin, whose only known target is throm-
bin, also had an inhibitory e¡ect. However, heparin did not
enhance the inhibitory e¡ect of ATIII and thrombin was un-
able to activate NF-UB in the cells. It is possible hirudin is
targeting membrane-associated thrombin which may not be
mimicked by the addition of free thrombin. We found that
LPS could activate a thrombin-like protease in THP-1 cells.
The activity was transient in nature, and required above nor-
mal concentrations of LPS. The e¡ect was subtle but consis-
tent, which would be expected if LPS were activating a speci¢c
serine protease, generating a speci¢c ligand.
Though no explicit evidence has been shown supporting
direct binding between LPS and TLR4, two studies have
been published suggesting such a direct interaction [17,29].
Lipid IVa, a partial structure of the active LPS moiety Lipid
A, acts as an agonist on mouse TLR4, but is an antagonist in
humans. Transfection of mouse macrophages with human
TLR4 conferred an antagonist e¡ect to Lipid IVa, while hu-
man macrophages transfected with mouse TLR4, detected
Lipid IVa as an agonist [29]. These ¢ndings suggest that
TLR4 alone is able to determine the response to Lipid IVa.
Other data suggests that MD2 is responsible for this species-
speci¢c pharmacology [30]. In the absence of direct binding
data, it is di⁄cult to evaluate these data. While it is likely that
TLR4 and MD2 are involved in LPS recognition, anti-TLR4
antibodies that inhibit LPS-induced NF-UB-dependent gene
expression were unable to reduce radiolabelling of TLR4
and MD2 complex [17]. This suggests that additional steps
are required for cell activation, besides the close proximity
of LPS to TLR4 and MD2. The authors suggest that the
antibody interferes with oligomerisation. Another possibility
is that the antibody blocks the binding of an endogenous li-
gand. The clear close proximity of LPS to CD14, MD2 and
TLR4 does not exclude the possibility of a further protein
binding LPS and triggering a serine protease cascade, which
results in a ligand for TLR4.
In conclusion, our data suggest that the rapid activation of
a serine protease is required for TLR4 function. It is possible
that TLR4 binding is required for protease activation, the
resulting ligand acting via TLR4, in an analogous manner
to Spaetzle and Toll in Drosophila. Further studies to identify
the protease involved are underway.
Acknowledgements: The authors would like to thank Prof. Robin
Carrell for the generous gift of ATIII and L-ATIII used in this study.
This work was supported by the European Union Biomed 2 Program,
Grant number BMH4-CT-97-2453.
References
[1] Lemaitre, B., Nicolas, E., Michaut, L., Reichhart, J-M. and Ho¡-
man, J.A. (1996) Cell 86, 973.
[2] Imler, I. and Ho¡mann, J.A. (2000) Curr. Opin. Microbiol. 3, 16.
[3] Aderem, A. (2001) Crit. Care Med. 29, S1.
[4] Fitzgerald, K.A. and O’Neill, L.A.J. (2000) Microb. Infect. 2,
933.
[5] Bowie, A. and O’Neill, L.A.J. (2000) J. Leukoc. Biol. 67, 508.
[6] Belvin, M.P. and Anderson, K.V. (1996) Annu. Rev. Cell. Dev.
Biol. 12, 393.
[7] O’Neill, L.A.J. and Dinarello, C.A. (2000) Trends Immunol. To-
day 21, 206.
[8] Poltorak, A., He, X., Smirnova, I., Lui, M.Y., Hu¡el, C.V., Du,
X., Birdwell, D., Alejos, E., Silva, M., Galanos, C., Freudenberg,
M., Ricciardi-Castagnoli, P., Layton, B. and Beutler, B. (1998)
Science 282, 2085.
[9] Qureshi, S.T., Lariviere, L., Leveque, G., Clermont, S., Moore,
K.J., Gros, P. and Malo, D. (1999) J. Exp. Med. 189, 615.
[10] Takeuchi, O., Hoshino, K., Kawai, T., Sanjo, H., Takada, H.,
Ogawa, T., Takeda, K. and Akira, S. (1999) Immunity 11, 443.
[11] Lien, E., Sellati, T.J., Yoshimura, A., Flo, T.H., Rawadi, G.,
Finberg, R.W., Carroll, J.D., Espevik, T., Ingalls, R.R., Radolf,
J.D. and Golenbock, D.T. (1999) J. Biol. Chem. 274, 33419.
[12] Hemmi, H., Takeuchi, o., Kawai, T., Kaisho, T., Sato, S., Sanjo,
H., Matsumoto, M., Hoshino, K., Wagner, H., Takedo, K. and
Akira, S. (2000) Nature 408, 740.
[13] Hayashi, F., Smith, K.D., Ozinsky, A., Hawn, T.R., Yi, E.C.,
Goodlett, D.R., Eng, J.K., Akira, S., Underhill, D.M. and Ader-
em, A. (2001) Nature 410, 1099.
[14] Morisato, D. and Anderson, K.V. (1994) Cell 76, 677.
[15] LeMosy, E., Hong, C.C. and Hashimoto, C. (1999) Trends Cell
Biol. 9, 102.
[16] Levashina, E.A., Langley, E., Green, C., Gubb, D., Ashburner,
M., Ho¡mann, J.A. and Reichhart, J.M. (1999) Science 28, 1917.
[17] Correia, J.S., Soldau, K., Christen, U., Tobias, P.S. and Ulevitch,
R.J. (2001) J. Biol. Chem. 276, 21129.
[18] Mansell, A., Braun, L., Cossart, P. and O’Neill, L.A.J. (2000)
Cell. Microb. 2, 127.
Fig. 5. LPS induce thrombin-like protease activity. THP-1 cells
(7.5U104/ml) were stimulated with 10 Wg/ml of LPS. Samples were
diluted in phenol-red-free RPMI containing Chromozym TH and
spectrometrically assayed at relevant time points. Results are shown
as absorbance units per individual sample and are expressed as
means þ standard deviations of triplicate samples from three experi-
ments. Data indicate signi¢cant di¡erences (*P = 0.016 and
**P = 0.021) when compared with non-stimulated control values.
FEBS 25468 20-11-01
A. Mansell et al./FEBS Letters 508 (2001) 313^317316
[19] Bradford, M.M. (1970) Anal. Biochem. 72, 248.
[20] Bauer, K.A. and Rosenburg, R.D. (1991) Semin. Hematol. 28,
10.
[21] Jin, L., Abrahams, J.P., Skinner, R., Petitou, M., Pike, R.N. and
Carrell, R.W. (1997) Proc. Natl. Acad. Sci. USA 94, 14683.
[22] Raetz, C.R. (1990) Annu. Rev. Biochem. 59, 129.
[23] Hirchfeld, M., Ma, Y., Weis, J.H., Vogel, S.N. and Weis, J.J.
(2000) J. Immunol. 165, 618.
[24] Markwardt, F. (1994) Thromb. Res. 74, 1.
[25] Anrather, D., Millan, M.T., Palmetshofer, A., Robson, S.C.,
Geczy, C., Ritchie, A.J., Bach, F.H. and Ewenstein, B.M.
(1997) J. Immunol. 159, 5620.
[26] Ho¡man, M. and Cooper, S.T. (1995) Blood Cells Mol. Dis. 21,
156.
[27] Wardell, M.R., Chang, W.S., Bruce, D., Skinner, R., Lesk, A.M.
and Carrell, R.W. (1997) Biochemistry 36, 13133.
[28] Baeuerle, R.A. and Henkel, T. (1994) Annu. Rev. Immunol. 12,
141.
[29] Lien, E., Means, T.K., Heine, H., Yoshimura, A., Kusumoto, S.,
Fukase, K., Fenton, M.J., Oikawa, M., Qureshi, N., Monks, B.,
Finberg, R.W., Ingalls, R.R. and Golenbock, D.T. (2000) J. Clin.
Invest. 105, 497.
[30] Kawasaki, K., Akashi, S., Shimazu, R., Yoshida, T., Miyake, D.
and Nishijima, M. (2000) J. Biol. Chem. 275, 2251.
FEBS 25468 20-11-01
A. Mansell et al./FEBS Letters 508 (2001) 313^317 317
